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Abstract
Introduction: Schnitzler’s syndrome (SchS) is a disabling autoinflammatory disorder, characterized by a chronic
urticarial rash, an M-protein, arthralgia, and other signs of systemic inflammation. Anti-interleukin-1 (IL-1) beta
antibodies are highly effective, but the pathophysiology is still largely unknown. Here we studied the effect of
in-vivo IL-1 inhibition on serum markers of inflammation and cellular immune responses.
Methods: Eight patients with SchS received monthly subcutaneous (s.c.) injections with 150 mg canakinumab for
six months. Blood was drawn for measurement of serum markers of inflammation (12 times per patient) and for
functional and phenotypic analysis of both freshly isolated and toll-like receptor (TLR)-ligand-stimulated peripheral
blood mononuclear cells (PBMCs) (five times per patient). All data were compared to results of healthy controls.
Results: IL-6 levels in serum and in lysates of freshly isolated PBMCs and serum myeloid-related protein (MRP8)/14
and S100A12 levels correlated with disease activity. In vitro, LPS stimulation resulted in higher IL-6 and IL-1 beta
production in PBMCs from symptomatic SchS patients compared to healthy controls, whereas patient cells were
relatively hyporesponsive to poly:IC and Pam3Cys. The mRNA microarray of PBMCs showed distinct transcriptomes for
controls, symptomatic patients and anti-IL-1-treated patients. Numbers of T- and B-cell subsets as well as M-protein
concentrations were not affected by IL-1 inhibition. Free light chain levels were elevated in 4 out of 8 patients.
Conclusions: In conclusion, patient PBMCs are hyperresponsive to LPS, and clinical efficacy of IL-1 beta inhibition
in patients with SchS is associated with in-vivo and ex-vivo suppression of inflammation. Interestingly, patient
PBMCs showed divergent responses to TLR2/6, TLR3 and TLR4 ligands. Our data underscore that IL-1 beta plays a
pivotal role in SchS.
Introduction
Schnitzler’s syndrome (SchS) is a chronic disabling autoin-
flammatory disorder, characterized by a chronic urticarial
rash, a monoclonal component (M-protein), arthralgia
and other signs and symptoms of systemic inflammation,
with the long-term risk of development of a lymphoprolif-
erative disorder [1–3]. The mean age of onset is 51 years,
and a positive family history has never been reported. The
etiology is unknown, but a pathophysiological clue has
been provided by the efficacy of anti-interleukin-1 (IL-1)
treatment [1, 4–11], and IL-1β inhibition in particular
[12–14]. However, when IL-1 inhibition is discontinued,
symptoms will rapidly return after stopping the IL-1
receptor antagonist (IL-1Ra) anakinra, or will gradually
return after stopping canakinumab, a monoclonal anti-IL-
1β antibody. This implies that the disease process con-
tinues upstream of IL-1β [13]. Also, whereas markers of
systemic inflammation all normalize, M-protein concen-
trations remain unaffected during anakinra and canakinu-
mab treatment [13].
Previous case reports showed that peripheral blood
mononuclear cells (PBMCs) or monocytes from patients
with symptomatic SchS produced more IL-1β and IL-6
upon lipopolysaccharide (LPS)-stimulation compared to
control PBMCs [9, 15, 16]. Here, we studied the effect of
several toll-like receptor (TLR) ligands on IL-1β, IL-6
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and tumor necrosis factor alpha (TNFα) production by
PBMCs of eight classical and variant SchS patients, in-
cluding two variant patients with NLRP3 mosaicism that
were recently described [17]. Moreover, we performed
these experiments, as well as serum cytokine measure-
ments, leukocyte subset analyses and serum free light-
chain analyses, on blood samples collected during a
symptomatic episode, anakinra treatment, and at several
time points during a trial with canakinumab [13] in
order to investigate disease-specific characteristics and
the effect of IL-1 on these markers.
We showed that the clinical efficacy of IL-1β inhib-
ition in patients with SchS is associated with suppression
of inflammation, and that TLR4 is involved in the en-
hanced IL-1β production. We also identified MRP8/14
and S100A12 as markers of disease activity in SchS.
Methods
Patients and patient samples
The study was approved by the local medical ethical
committee of the Radboud university medical center, as
the patients and controls were recruited there. Eight
patients with SchS, either classical or variant type, and
seventeen healthy controls that were age- and sex-
matched as much as possible provided written informed
consent. Patients stopped anakinra in order to enter the
canakinumab trial and multiple blood samples were col-
lected [13]. Polymorphonuclear cells (PMNs) and per-
ipheral blood mononuclear cells (PBMCs) were isolated
during anakinra treatment, during disease relapse after
discontinuation of anakinra (symptomatic episode), 14
days and 6 months after the first monthly canakinumab
injection, and upon disease relapse after discontinuation
of canakinumab. At each time point, blood samples from
a matched healthy donor control were collected too. B cells
and T cells were isolated from blood samples collected dur-
ing anakinra, canakinumab and during the symptomatic
phase. Serum samples were also taken on those occasions,
as well as at 3 and 7 days and then monthly after the first
canakinumab injection.
PBMC and polymorphonuclear cells (PMNs) processing
PBMCs were isolated from EDTA-blood using Ficoll-
paque Plus (GE Healthcare, Eindhoven, The Netherlands)
separation, and PMNs were isolated from the pellet by lys-
ing erythrocytes with a hypotonic 155mM NH4Cl, 10 mM
KHCO3 lysis buffer. For RNA isolation, 5 million cells of
each sample were dissolved in 1 ml Trizol (Invitrogen,
Bleiswijk, The Netherlands) and stored until further pro-
cessing. For protein analysis, 6 million cells were lysed
with a lysisbuffer (50 mM Tris (pH 7.4), 150 mM NaCl,
2 mM EDTA, 2 mM ethylene glycol tetraacetic acid
(EGTA), 10 % glycerol, 1 % Triton X-100, 40 mM
β-glycerophosphate, 50 mM sodium fluoride, and 200
mM sodium vanadate, supplemented with protease
inhibitor cocktail (Roche, Mannheim, Germany)) and
stored at −80 °C until measurement.
PBMC culture
PBMCs isolated at the five indicated time points were
also used for in vitro experiments. Cells from patients
(N = 8) and controls (N = 17) were stimulated for 24 hours
with LPS (TLR4 ligand, 0.1, 1, 10 ng/ml) (Sigma, St Louis,
MO, USA; Escherichia coli serotype 055:B5, purified in our
own laboratory), Pam3Cys (TLR2 ligand, 10 μg/ml) (EMC
Microcollections, Tubingen, Germany), poly:IC (TLR3 lig-
and, 5 μg/ml) (InvivoGen, Toulouse, France), or no ligand.
For IL-17 assays, cells were stimulated for 7 days with
heat-killed (homemade) Candida albicans (10^6/ml). Su-
pernatants were collected and stored at −80 °C. Cytokine
concentrations in serum, supernatants and lysates were
measured by means of enzyme-linked immunosorbent
assay (ELISA): IL-1β (R&D, DY 201E, Minneapolis, MN,
USA), IL-6 (Sanquin, M9316, Nijmegen, The Netherlands),
TNF-α (R&D, DY210E), IL-17 (R&D, DY317E), MRP8/14
and S100A12 as previously described [18, 19].
RNA extraction and quantitative real-time polymerase
chain reaction (qPCR)
mRNA was extracted and first-strand cDNA was gener-
ated and amplified by means of qPCR as previously de-
scribed [20]. Specific qPCR primers were designed with
Primer Express 1.0 Software (Applied Biosystems) and
purchased from Biolegio (Nijmegen, The Netherlands).
By means of the comparative delta-DCt method, relative
mRNA expression levels of all examined genes were cal-
culated [21].
Microarray
A microarray using the Illumina Direct Hybridization
Assay (performed by ServiceXs, Leiden, The Netherlands)
was performed on purified whole blood RNA samples
from two patients with classical SchS and 1 IgG variant
case with myeloid-restricted NLRP3 mosaicism. Integrity
of the RNA samples was confirmed by Eukaryote Total
RNA Nano Bioanalyzer analysis. The microarray data
were further analyzed by loading the log expression values
into Partek Genomics Suite Software (Version 6.4; Partek,
Inc., St Louis, MO, USA). Quantile normalization was per-
formed including all arrays, to correct for large overall ex-
pression differences between the arrays. In addition, to
adjust for the baseline expression level of each of the indi-
vidual patients in the different subgroups, a correction for
the factor ‘individual’ was performed, as one would do for
batch correction, using the batch remove option from the
software. On 1 August 2015, the data will be released on-
line in the Gene Expression Omnibus [GSE70019].
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Flow cytometric analysis
T-lymphocyte subsets
To detect intracellular expression of the transcription
factors Foxp3, RORγt and Tbet in CD3+CD4+ T cells,
Ficoll-isolated PBMCs were first labeled with CD3
(UCHT1)-ECD and CD4(SFCI12T4D11)-PC7 (Beckman
Coulter), and subsequently fixed and permeabilized using
Fix/Perm buffer (eBioscience), labeled with FoxP3
(PCH101)-FITC (eBioscience), RORγt(AFKJS-9)-APC and
T-bet(4B10)-PE (Santa Cruz Biotechnology, Santa Cruz,
CA) and measured by five-color flow cytometry (FC500,
Beckman Coulter). Data were analyzed using CXP soft-
ware (Beckman Coulter). Isotype controls were used for
gate settings.
B-lymphocyte subsets
Cells from heparinized blood were phenotypically ana-
lyzed in a 10-color MoAb conjugate combination using
a Navios™ instrument with 10-color PMTs and three
solid-state lasers (Beckman Coulter, Fullerton, FL). The
list mode data files were further analyzed using Kaluza™
software (Beckman Coulter). In order to guarantee that
the optics, laser, fluidics and fluorescence intensity were
stable during all measurements calibration was performed
using Flow Check Pro Fluorospheres (Beckman Coulter)
and Cyto-Cal Multifluor + Violet Fluorescence Alignment
Beads (Thermo Scientific, Fremont, CA, USA). After
erythrocyte lysis (BD Pharm-Lyse, BectonDickinson) cells
were washed with PBS with 1 % bovine serum albumin
before being labeled with fluorochrome-conjugated mAbs.
After incubation for 30 minutes at 4 °C in the dark, cells
were washed twice to remove unbound antibodies and an-
alyzed. For cell surface staining, the following mAbs were
used: IgD-FITC, IgM-PE (both Dako, Denmark) and CD3-
ECD, CD4-PECy5.5, CD27-PECy7, CD20-PacB, CD45-
KromeOrange, CD56-APC, CD8-APC-Alexa Fluor700
and CD19-APC-Alexa Fluor750 (all Beckman Coulter,
Marseille, France). Subsequently, the various lymphocyte
subpopulations were analyzed on the flow cytometer using
CD45/SSC to gate the lymphocyte population.
M-protein and free light chain analysis
To detect and quantify the presence of an M-protein,
agarose gel electrophoresis and immunofixation were
performed on the Hydrasys (Sebia, Evry, France) accord-
ing to the manufacturer’s protocol. Serum free light-chain
analysis was performed on a BNII analyzer (Siemens,
Marburg, Germany) using Freelite reagents (The Binding
Site Ltd, Birmingham, UK) according to the manufac-
turer’s protocol.
Statistical analysis
Repeated-measures analysis of variance (ANOVA) using
SPSS v16.0 (SPSS Inc) was performed on the delta-cycle
threshold (dCt) values of the qPCR data corrected for
primer efficiency. dCt is the difference between the Ct of
the target gene and the reference gene (RPLP0). The
ELISA data were analyzed by one-way ANOVA with
Bonferroni post hoc testing for the models. Fold changes
and p values of the microarray data for the contrast, pa-
tients vs. controls, were calculated by conducting multi-
factorial ANOVA on the factor ‘treatment’.
Results
Proinflammatory cytokines and S100 proteins in serum,
PBMCs and PMNs
Proinflammatory cytokine concentrations were measured
in serum from patients under anakinra, during symptoms,
and several time points upon initiating canakinumab treat-
ment. Compared to controls, serum IL-6 was elevated in
all patients during active disease, to become undetectable
or very low during anakinra or canakinumab treatment
(Fig. 1a). The presence or absence of NLRP3 mosaicism
did not make a difference. IL-17 was undetectable in all
serum samples and TNF-α in most serum samples. Serum
IL-1β was undetectable or very low in the samples taken
during anakinra treatment and during active disease.
Because binding to the administered antibodies probably
interferes with detection, IL-1β could not be reliably
measured during canakinumab treatment. Interestingly,
clinical relapse was not associated with a rise in IL-6 con-
centrations. Cell-associated IL-6 concentrations (measured
in lysates from PBMCs that were directly lysed after sam-
pling) were also high during the symptomatic phase, and
correlated with serum IL-6 concentrations (R2 = 0.86,
Fig. 1b, c). We could not detect any IL-1β, IL-6 or IL-17
protein in neutrophil lysates.
Myeloid-related protein 8 (MRP8, or S100A8), MRP14
(S100A9) and S100A12 are known indicators of systemic
inflammation [22–24]. Serum MRP8/14 and S100A12
concentrations corresponded with disease activity in all
SchS patients as they were increased during symptom-
atic episodes and decreased during in vivo IL-1 inhib-
ition (Fig. 1d, e). The clinical relapse in patient 8 and
presence of minimal symptoms in patient 7 at day 28 after
the first canakinumab dose were reflected by relatively
high MRP8/14 and S100A12 concentrations, whereas
serum IL-6 concentrations were only marginally increased
(Figure a, d, e) [13]. MRP8/14 and S100A12 concentra-
tions in active SchS (median 3,905 and 485 ng/ml, res-
pectively) were higher than in reported healthy controls
(median 340 ng/ml and 120 ng/ml, respectively) [24, 25],
and in anakinra-treated patients (median 945 and 133 ng/
ml, respectively) and canakinumab-treated patients (me-
dian 1,195 and 125 ng/ml, respectively). Interestingly,
MRP8/14 serum levels during IL-1 inhibition were signifi-
cantly higher than in the reported healthy controls. The
patient data had considerable heterogeneity. The S100A12
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data correlated with the MRP8/14 data (R2 = 0.92, 0.94
and 0.85, respectively).
As neutrophils were reported to possess IL-1β process-
ing capacity [26], we measured cytokine mRNA expression
levels of circulating PMN cells of controls and of patients
with active disease or during IL-1 inhibition. During at-
tacks and during treatment episodes we found significant
expression of IL1B and IL1RN mRNA in neutrophils from
two out of two SchS patients, and these levels were similar
in two control samples (data not shown).
Microarray of circulating PBMCs
As an unbiased approach, we performed a transcriptome
analysis of RNA from PBMCs from three patients with
SchS (one with the NLRP3 mosaicism in myeloid cells)
and three matched controls. To investigate the effect of
IL-1 inhibition on gene expression, we analyzed patient
samples drawn during symptomatic disease, and anakinra
and canakinumab treatment. Assessment of unsupervised
clustering of gene expression levels, normalized for the ef-
fect of the individual, revealed that controls, symptomatic
patients, and treated patients were in separate clusters,
with the largest difference between control and symptom-
atic patient samples (Additional file 1: Figure S1A).
Additional file 1: Figure S1B shows the clustering of
the samples for the most significantly upregulated and
downregulated genes in the symptomatic patients. Com-
parison of symptomatic patients to patients during IL-1
inhibition showed that S100A12 and IL-1B are among
the most differentially expressed genes during active dis-
ease. Both genes were significantly higher expressed in
symptomatic patients than in anti-IL-1-treated patients
Fig. 1 Serum concentrations of IL-6, myeloid-related protein (MRP)8/14 and S100A12, and peripheral blood mononuclear cell (PBMC)-associated
IL-6 correlate with disease activity. a Serum IL-6 levels in controls, and in Schnitzler’s syndrome (SchS) patients with or without NLRP3 mosaicism
during anakinra (IL-1Ra) treatment, a symptomatic episode, at several time points during a canakinumab (anti-IL-1β antibody) trial, and during
relapse after canakinumab withdrawal. b IL-6 concentration in lysates of freshly isolated PBMCs from SchS patients with or without NLRP3
mosaicism. c Correlation between serum and cell-associated IL-6 concentrations in SchS patients. d Serum MRP8/14 and e S100A12 concentrations
during anakinra treatment, a symptomatic episode, and 28 days after a single injection of canakinumab
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and in controls, but mRNA levels during canakinumab
or anakinra therapy did not differ significantly from those
in controls. qPCR analysis confirmed the corresponding
microarray data (Additional file 1: Figure S2).
Differential production of proinflammatory cytokines by
patient PBMCs stimulated with TLR ligands
We assessed the proinflammatory response to LPS,
Pam3Cys and poly:IC stimulation of control PBMCs and
of patient PBMCs, sampled either in the symptomatic
phase or during treatment with anakinra or canakinu-
mab. As PBMCs of our two patients with myeloid mo-
saicism of NLRP3 variants constitutively produced high
levels of IL-1β and IL-6, whereas PBMCs of controls and
patients without this mosaicism did not [17], we ana-
lyzed the results of the former separately (see below). In
PBMCs of all patients sampled during a symptomatic
episode, IL-1β, IL-6 and TNF-α production was higher
than in healthy controls when the cells were exposed to
1 ng/ml LPS (Fig. 2, significance of the models, p = 0.002,
0.035, and 0.076, respectively). There was a clear dose re-
sponse for cells exposed to 0.1 and 1.0 ng/ml LPS (data
not shown). In controls and during treatment with canaki-
numab, the IL-1β production induced by LPS was lower
(Fig. 2, p <0.001 and 0,003, respectively). LPS-induced
IL-6 production was significantly elevated in PBMCs dur-
ing the symptomatic phase compared to controls and
during anti-IL-1β treatment (Fig. 2b, p = 0.04 and <0.001,
respectively). Due to an outlier, this was significant for
anakinra. The patients with the highest responses were all
the classical IgM type and had a more severe phenotype
than the others. No clear difference in proinflammatory
cytokine production between patients and controls was
found upon stimulation with LPS 10 ng/ml. In vitro
addition of IL-1Ra only marginally inhibited IL-1β and
IL-6 production (at the highest LPS concentration (10 ng/
ml)) in PBMCs of all SchS patients (data not shown).
When cells of SchS patients and controls were exposed
to Pam3Cys, production of IL-1β and IL-6 was signifi-
cantly lower in the patients than in controls. On exposure
to poly:IC this was not significant, but there was a clear
trend (Pam3Cys IL-1β pooled patient data versus controls
p = 0.006; Pam3Cys IL-6 pooled patient data versus con-
trols p = 0.037; poly:IC IL-1β pooled patient data versus
controls p = 0.058; poly:IC IL-6 pooled patient data versus
controls p = 0.115). Interestingly, the treatment condition
did not affect this production (Fig. 3).
In PBMCs of the two patients with myeloid NLRP3
mosaicism (patients 7 and 8), high baseline (hence un-
stimulated) IL-1β and IL-6 production was seen, as pre-
viously reported. Addition of IL-1Ra in vitro inhibited
this production, pointing to autocrine or paracrine cyto-
kine production mediated by IL-1 [17]. In one of these
patients (patient 7), the unstimulated production of IL-6
and IL-1β was lower during IL-1 blocking treatment
than during the symptomatic phase. LPS, Pam3Cys and
poly:IC induced production of both cytokines during the
symptomatic episode in this patient. This was also re-
duced during both anakinra and canakinumab treatment.
The data for patient 8 were inconsistent (Additional file 1:
Figure S3). However, in both patients, the production of
IL-1β and IL-6 was dose-dependent over a range of 0.1 to
10.0 ng/ml LPS (data not shown). After 7 days stimulation
with heat-killed Candida albicans, IL-17 production by
PBMCs from patients and controls was similar, irrespect-
ive of the disease status of the patients (data not shown).
Fig. 2 Lipolysaccharide (LPS)-induced production of IL-1β, IL-6, and TNFα in peripheral blood mononuclear cells (PBMCs) sampled during active
disease and IL-1-blocking treatment. PBMCs of patients with Schnitzler’s syndrome (SchS) without NLRP3 mosaicism were sampled during anakinra
treatment, a symptomatic episode, at several time points during a canakinumab trial, and during relapse after canakinumab withdrawal. These
PBMCs and those of healthy controls were stimulated with 1 ng/ml LPS for 24 hours, and supernatants were collected for ELISA of IL-1β, IL-6
and TNFα concentrations. Bars indicate median values. *p <0.05, **p <0.01, ***p <0.001
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T and B lymphocyte analyses
Circulating T and B lymphocyte subsets were analyzed
by means of flow cytometry during active disease and
under anakinra and canakinumab treatment. Numbers of
regulatory T cells and expression levels of Foxp3 were
similar in patients during different treatment settings and
in controls, and there was no difference in RORyT+ cells
(Additional file 1: Figure S4). Regulatory T cell suppressor
function as studied in a co-culture suppression assay
appeared unaffected - we found no difference between pa-
tient and control cells (n = 1; data not shown). There were
also no B-lymphocyte subset changes during the different
treatment settings (Additional file 1: Figure S5).
M-protein and serum free light-chain concentrations
In our patients, the serum concentration of the M-protein,
the diagnostic hallmark of SchS, was not related to disease
activity. IL-1 inhibition did not affect paraprotein concen-
trations in our patients either during several years of
anakinra treatment or during canakinumab treatment for
6 months. Moreover, in our two patients with the most se-
vere phenotype and in which NLRP3 somatic mosaicism
was found in myeloid cells, only unquantifiable IgG kappa
was found (Table 1).
The ratio of serum kappa and lambda free light-chain
levels was reported to be a prognostic factor for disease
progression in multiple myeloma and other monoclonal
gammopathies [27–29]. Hence, we measured this ratio in
eight patients, in two of whom it was abnormal, especially
in a female patient with strongly elevated kappa light-chain
levels. In these and two other patients who had increased
free light-chain levels, we tested free light-chains during
symptoms and during treatment with IL-1 inhibition. We
observed no significant changes in serum free light-cchain
Fig. 3 Pam3Cys- and poly:IC-induced production of IL-1β, IL-6, TNFα in peripheral blood mononuclear cells (PBMCs) sampled during active
disease and IL-1-blocking treatment. PBMCs of patients with Schnitzler’s syndrome (SchS) without NLRP3 mosaicism were sampled during anakinra
treatment, a symptomatic episode, at several time points during a canakinumab trial, and during relapse after canakinumab withdrawal. These
PBMCs and those of healthy controls were stimulated with Pam3Cys 10 μg/ml (a), or poly:IC 5 μg/ml (b) for 24 hours, and supernatants were
collected for ELISAs of IL-1β, IL-6 and TNFα concentrations. Bars indicate median values
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concentrations in symptomatic SchS patients versus pa-
tients in remission due to IL-1 inhibition (Table 1).
Discussion
Here, we described the inflammatory response during the
symptomatic phase of SchS, during treatment with either
anakinra or canakinumab, and during relapse after canaki-
numab withdrawal. During the symptomatic phase, the cir-
culating concentrations of IL-6 were elevated, as were the
protein concentrations of IL-6 and mRNA levels of IL-1β
in circulating PBMCs. In this phase there was also aug-
mented LPS-induced production of IL-1β and IL-6. Finally,
the MRP8/14 and S100A12 concentrations in serum and
S100A12 mRNA levels in PBMCs were elevated. All of
these were normalized during treatment with either IL-1Ra
or anti-IL-1β antibodies, and both therapies led to a shift of
the PBMC transcriptome towards the mRNA signature of
healthy controls. Clinical relapse several months following
canakinumab withdrawal was not associated with a rise in
IL-6 serum concentrations, nor with increased ex vivo cyto-
kine production by PBMCs. Interestingly, irrespective of
the treatment condition, PBMCs from SchS patients pro-
duced less IL-1β and IL-6 when exposed to Pam3Cys or
poly:IC when compared to controls.
Table 1 M-protein and serum free light-chain levels during IL-1 inhibition
Patient Sex Treatment M-protein Serum free light-chains
number subtype g/L kappa (mg/l) lambda (mg/l) Ratio κ / λ
1 M Anakinra IgMκ & IgMλ 10.1 14.4 46.8 0.31
None (Day 4 after anakinra withdrawal) 7.7 14.7 53.9 0.27
Canakinumab day 28 10.6 18.6 51.0 0.36
Relapse (post-canakinumab) 9.3
2 F None (pre-anakinra) IgGκ 6.8 88.3 12.4 7.12
Anakinra 5 59.9 9.4 6.35
None (day 5 after anakinra withdrawal) 4.1 69 13.5 5.11
Canakinumab Day 28 4.3 59.1 11.6 5.09
Relapse (post-canakinumab) 3.7 78.4 12.2 6.43
3 M None (day 5 after anakinra withdrawal) IgMκ 2.7
Canakinumab day 28 3.5 19.1 19.8 0.96
4 M Anakinra IgGκ 2.9
None (day 5 after anakinra withdrawal) 2.8
Canakinumab day 28 3.2 14 10.3 1.36
Relapse (post-canakinumab) 2.5
5 M Anakinra IgMκ 4.4
None (day 6 after anakinra withdrawal) 4.5 19.4 12.4 1.56
Canakinumab day 28 5
Relapse (post-canakinumab)
6 M Anakinra IgMκ 6.8 25.5 20.6 1.24
None (day 4 after anakinra withdrawal) 6.1 29.2 15.8 1.85
Canakinumab day 28 5.6 29.3 17.9 1.64
Relapse (post-canakinumab) 6.3
7 F Anakinra IgGκ n.d.
None (day 3 after anakinra withdrawal) n.d. 15.3 15.1 1.01
Canakinumab day 28 n.d.
Relapse (post-canakinumab) n.d.
8 M Anakinra IgGκ n.d. 17 13.5 1.26
None (day 5 after anakinra withdrawal) n.d. 26.9 18.7 1.44
Canakinumab day 14 p.n.q. 18.4 18.1 1.02
Canakinumab day 28 (relapse) p.n.q. 23.9 23.2 1.03
Free light-chains in the serum were measured with the Freelight assay, reference values: serum free kappa chains (3.3−19.4 mg/l); serum free kappa chains (5.7−26.3
mg/l); ratio kappa/labda light-chains (0.26−1.65). Abnormal values are indicated in bold. n.d. not detectable; p.n.q. present but not quantifiable
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Taken together, our data point to an IL-1β-driven dis-
order, which is in line with the clinical efficacy of IL-1β
inhibition and with the few reports on in vitro findings.
Recently, we reported two variant SchS patients with
NLRP3 mosaicism in the myeloid lineage, in whom
PBMCs produced high constitutive levels of IL-1β and
IL-6, which was abolished by in vitro addition of IL-1Ra
[17]. Previously, a few SchS cases were described in
which PBMCs or monocytes from symptomatic patients
produced more IL-1β and IL-6 upon LPS stimulation
compared to control PBMCs [9, 15, 16], and that this
could be reversed by in vivo anakinra treatment [15].
Spontaneous IL-1β production by PBMCs was present
in one more patient [16], but absent in others [15].
In our patients with NLRP3 mosaicism, the hyperpro-
duction of IL-1β is probably due to an overactive NLRP3
inflammasome. In those without this genetic defect the
trigger of the enhanced IL-1β production is still unclear.
The increased IL-1β concentrations in turn lead to pro-
duction of IL-6 and an autocrine or paracrine produc-
tion of more IL-1β. The latter became clear from the
striking reduction in spontaneous IL-1β and IL-6 pro-
duction by PBMCs from the two NLRP3 mosaic patients
when IL-1Ra was added in vitro [17], the reduced IL1B
mRNA levels in circulating PBMCs during in vivo IL-1
inhibition, and the lower LPS-induced IL-1β and IL-6
production in PBMCs sampled during treatment.
The increased downstream production of cytokines
leads to an enhanced acute phase response with eleva-
tion of C-reactive protein (CRP). The amount of IL-6,
which is readily measurable in the circulation, is prob-
ably responsible for the fever and other signs of systemic
inflammation.
How should we envisage the lack of a rise in serum
IL-6 and the still downregulated cytokine production
when the patients relapsed several months after canaki-
numab withdrawal? Probably the best explanation is that
the relapse is compartmentalized in its early phase, pos-
sibly at the level of the skin, which is continuously ex-
posed to pathogen-associated molecular patterns as well
as endogenous ligands of pattern recognition receptors
(PRRs). Indeed, PRRs were implicated in the pathophysi-
ology of other inflammatory skin diseases, such as AIM2
(absent in melanoma 2) and dectin-1 in psoriasis [30–32].
The IL-1β positive mast cells we recently identified in
SchS skin might not only be involved in the chronic urti-
caria (de Koning et al., submitted), but also in the induc-
tion of systemic inflammation.
As the triggers of the IL-1β production are currently
unclear, it is of great interest that we find that TLR4
plays a clear role - and not TLR2, TLR3 and TLR6. It
implies that either exogenous TLR4 ligands (such as
LPS) or putative endogenous TLR4 ligands (like heat-
shock proteins, minimally modified LDL, HMGB1, SAA3,
MRP8/14, and S100A12 [33, 34]) function as triggers for
the attacks. Especially, MRP8/14 and S100A12 are inter-
esting in this regard, as serum levels are associated with
disease activity in SchS. Several in vitro studies and mouse
models of other inflammatory skin diseases have demon-
strated a role for TLR4, e.g., nickel-induced allergic
contact dermatitis and graft versus host disease [32]. Intri-
guingly, expression of both TLR4 and NLRP3 mRNA is
extremely low in healthy epidermis, which one might con-
sider a protective strategy preventing continuous stimula-
tion by constituents of the microbiome, for example [31].
We detected a relatively decreased responsiveness to
Pam3Cys (TLR2/6 ligand) and poly:I:C (TLR3 ligand) of
the SchS patient PBMCs (sampled both during symptoms
and anti-IL-1 treatment) compared to control PBMCs. To
our knowledge, such divergent responses to TLR2, TLR3,
TLR6 and TLR4 ligands have not been reported in inflam-
matory diseases before. We speculate that the relative hy-
poresponsiveness to TLR2 and TLR3 ligands might be a
protective mechanism in response to the enhanced proin-
flammatory response to TLR4 ligands.
Our findings of elevated spontaneous cytokine produc-
tion are reminiscent of findings in patients with the
cryopyrin-associated periodic syndrome CAPS in which
systemic inflammation is caused by activating NLRP3
mutations. CAPS patient PBMCs constitutively produce
IL-1β, and treatment with IL-1Ra results in both a dra-
matic clinical improvement and substantive downregula-
tion of LPS-induced IL-1β secretion by the patients’ cells
in vitro [35]. Typically, the enhanced proinflammatory re-
sponse to lower LPS concentrations that we observed in
SchS is also seen in other autoinflammatory diseases,
whereas at the relatively high concentration of 10 ng/ml,
the difference is much smaller or absent [36].
Hence, current and previous findings suggest that an
inflammasome is primed in PBMCs in SchS as in CAPS,
which explains a substantial IL-1β release in the absence
of the second hit that is usually required. Also, the relative
hyporesponsiveness to TLR2/6 and TLR3 agonists (in this
study) and ATP [16], and low IL18 mRNA levels in mono-
cytes despite high IL-18 serum levels [37] suggest the
presence of several negative feedback mechanisms.
We previously reported that in the two patients with
NLRP3 mosaicism in the myeloid cell lineage, high con-
stitutive IL-1β and IL-6 production by PBMCs was
blocked by in vitro addition of IL-1Ra [17]. Here we show
that this high baseline production was not impaired or
was only partially impaired while patients were treated
with IL-1 inhibitors. This implies ongoing activation of
IL-1β, and may explain why these two patients had the
most severe phenotypes and their disease quickly relapsed
upon cessation of anti-IL-1 treatment [13]. TLR2/6 and
TLR4 ligands induced the production of IL-1β and IL-6 in
these two patients, but a TLR3 ligand did not.
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In this study we additionally monitored S100 proteins,
B cell and T cell subsets, M-proteins and serum free
light-chains. S100A8/A9 (MRP8/14) and S100A12 are
secreted after activation of phagocytes via a so-called
alternative secretory pathway and cause strong proin-
flammatory effects on phagocytes and endothelial cells
in vitro [24]. S100A8 and S100A9 and S100A12 have
been shown to act as endogenous TLR-4 ligands and
binding of S100 proteins to TLR-4 consequently induces
NFκB expression via the MyD88-dependent pathway
[33, 34]. Besides their pathophysiological role as DAMPs
S100 proteins are regarded as markers of systemic in-
flammation [22–24] and especially in CAPS, both
MRP8/14 and S100A12 levels mirrored disease activity,
and were suggested as a sensitive marker even for sub-
clinical disease [23, 38]. In CAPS patients responding
to canakinumab treatment S100A8/A9 serum levels
already dropped to the range of normal controls within
8 days [25].
In our study, S100A12 mRNA levels were significantly
higher in circulating PBMCs from symptomatic patients
than in PBMCs from treated patients and controls, and
serum protein levels of both MRP8/14 and S100A12
correlated with disease activity. In a previous report,
serum S100A12 protein levels did not correlate with dis-
ease activity in SchS, which might be related to the
higher levels found in that study [5]. In most patients,
MRP8/14 levels were higher than in healthy controls,
even when they were asymptomatic under anakinra or
canakinumab treatment [24]. Thus, MRP8/14 and S10012
levels are markers of disease activity in SchS. The patient
data showed considerable heterogeneity, and in several pa-
tients persistent elevated MRP8/14 levels under treatment
were found compared to healthy controls, as was previ-
ously reported in CAPS patients [38]. This may indicate
subclinical disease activity that is not detected by CRP or
IL-6 measurements.
Previously, an increase in transitional B cells, decrease
in switched-memory B cells and low levels of peripheral
blood plasma cells were reported in a patient with SchS
when compared to healthy controls. IL-1Ra treatment
had no effect on the patient’s B lymphocytes or the IgM
M-protein [39]. Our analyses on T cell and B cell subsets
showed no differences between active disease and anti-
IL-1 treatment, neither were there any differences in T
cell subsets between patients and controls. We do not
know if long-term IL-1 inhibition would affect the T and
B cell compartments.
An M-protein is one of the diagnostic hallmarks of Schs.
We demonstrated that it is not a marker for disease activ-
ity as the serum concentration of the M-protein was not
affected by IL-1 inhibition. Moreover, in our two most se-
verely affected patients, only unquantifiable IgG kappa
was found. Still, it cannot be excluded that long-term
anti-IL-1 treatment could halt a progressive increase in
M-protein concentration in view of the B cell activating
property of IL-1β (the longest treatment duration of SchS
patients on continuous anti-IL-1 treatment is currently 8
years). Moreover, long-term follow up of many SchS pa-
tients is needed to determine if IL-1 inhibition can prevent
progression to a lymphoproliferative disorder. Indeed, in
some patients with smoldering or indolent multiple mye-
loma, who were at risk of progression to active myeloma,
concomitant treatment with IL-1Ra and dexamethasone
was found to decrease the myeloma proliferative rate [40].
The ratio of serum immunoglobulin kappa and lambda
light-chain levels is a prognostic factor for multiple mye-
loma disease progression [27, 28]. No such correlation
was seen in our SchS patient cohort, but in one case, the
highest free light-chain level was found prior to starting
treatment with IL-1 inhibition. More measurements com-
paring pre- and post-IL-1 inhibition serum light-chain
levels are needed to examine a possible association. We
conclude that both the intact M-protein and the free
light-chain concentrations are stable biomarkers in SchS
patients, and are not affected by disease status or thera-
peutic intervention.
Conclusions
Clinical efficacy of IL-1β inhibition in patients with SchS
is associated with suppression of inflammation. We identi-
fied MRP8/14 and S100A12 as markers of disease activity
in SchS. Our collective data underscore that IL-1β plays a
pivotal role in SchS, and that TLR4 is involved in the
enhanced IL-1β production. Future studies should be di-
rected at the mechanism behind the differential responses
to different TLR ligands and what drives the pivotal TLR4
response in the disease process.
Additional file
Additional file 1: Figure S1. Microarray data. A Unsupervised clustering
of microarray data of peripheral blood mononuclear cells (PBMCs) from
healthy controls (ctr), Schnitzler’s syndrome patients (pat) with active
disease, and Schnitzler’s syndrome patients treated with anakinra (ana) or
canakinumab (can). B Clustering of the samples for the most significantly
upregulated and downregulated genes in the symptomatic patients.
Figure S2 Quantitative polymerase chain reaction (qPCR) validation of
IL1B and S100A12 mRNA expression. IL1B and S100A12 mRNA expression
in PBMC from controls (N = 18) and patients (N = 8) during anakinra
treatment, canakinumab treatment, during symptoms, or during relapse
after canakinumab withdrawal were evaluated by means of qPCR assays.
Figure S3 Spontaneous and TLR2/6-/3-/4-stimulated production of IL-1β
and IL-6 in PBMCs of NLRP3 mosaic patients. BMCs of patients with
Schnitzler’s syndrome (SchS) with NLRP3 mosaicism that were sampled
during a symptomatic episode, anakinra treatment, and canakinumab
treatment were exposed to lipolysaccharide (LPS) 1 ng/ml, Pam3Cys 10
μg/mL poly:IC 5 μg/ml, or no stimulus for 24 hours, and supernatants
were collected for ELISA of IL-1β (A), and IL-6 concentrations (B).
Figure S4 No correlation treatment status with absolute numbers in
several T-cell subsets. Several T-cell subsets were assessed by means of
fluorescence-assisted cell-sorting during a symptomatic episode, during
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anakinra or canakinumab treatment, and at the time of relapse after
canakinumab withdrawal. FOXP3+ cells, RORγt+ cells and CD25+CD127-
(T regulatory) cells were measured in healthy controls and in patients
with SchS during canakinumab treatment (N = 8) or relapse (N = 4).
Figure S5 No correlation treatment status with absolute numbers in
several B-cell subsets. Several B-cell subsets were assessed by means of
fluorescence-assisted cell-sorting during a symptomatic episode, during
anakinra or canakinumab treatment, and at the time of relapse after
canakinumab withdrawal.
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